The 18th Meeting of the International Society of Amyloidosis was held in Heidelberg, Germany, from September 4-8. This meeting brought together experts as they discussed novel therapies, clinical trial updates, and the diagnosis and management of amyloidosis.
View all videos

ISA 2022

The 18th Meeting of the International Society of Amyloidosis
04–08 September 2022 | Heidelberg, Germany / Online

It was an absolute pleasure to talk with our friends from @VJHemOnc about the non-for-profit AI solutions that we are developing to extend precise prognostication in MF and MDS to all healthcare systems. @ASH_hematology #GEMFIN @gesmd @_pethema @idis_research https://twitter.com/VJHemOnc/status/1621418665609412609

VJHemOnc@VJHemOnc

🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?

Check out our interview with @MosqueraOrgeira below:

👉http://ow.ly/zJYI50MzXgg👈

@ASH_hematology #ASH22 #MPNsm #HemOnc #AI

This year's #ASH22 meeting brought so many updates in multiple myeloma, including novel CAR-T therapies, BiTEs, trial updates, and more!

To stay up-to-date with the latest, visit our post-ASH virtual workshop on-demand content:

👉http://ow.ly/jhhB50MHyo6👈

#MMsm #ImmunoOnc

🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?

Check out our interview with @MosqueraOrgeira below:

👉http://ow.ly/zJYI50MzXgg👈

@ASH_hematology #ASH22 #MPNsm #HemOnc #AI

📣 Check out our latest weekly podcast, where you will hear from experts @mike_dickinson1 & Tycel Phillips (@LymphClinician), who share their highlights in NHL at #ASH22:

🎧: http://ow.ly/5whs50MHIP4

#LymSM #HemOnc #ImmunoOnc

Each time I read an #AMLsm paper report morphological leukemia free state (MLFS) as a response criterion I cringe! While MLFS is listed in ELN criteria, it is not validated as proxy for long term benefit & does not reflect meaningful short term benefit to patients! Do you agree?

Load More...

ISA 2022

The 18th Meeting of the International Society of Amyloidosis
04–08 September 2022 | Heidelberg, Germany / Online
The 18th Meeting of the International Society of Amyloidosis was held in Heidelberg, Germany, from September 4-8. This meeting brought together experts as they discussed novel therapies, clinical trial updates, and the diagnosis and management of amyloidosis.
View all videos

It was an absolute pleasure to talk with our friends from @VJHemOnc about the non-for-profit AI solutions that we are developing to extend precise prognostication in MF and MDS to all healthcare systems. @ASH_hematology #GEMFIN @gesmd @_pethema @idis_research https://twitter.com/VJHemOnc/status/1621418665609412609

VJHemOnc@VJHemOnc

🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?

Check out our interview with @MosqueraOrgeira below:

👉http://ow.ly/zJYI50MzXgg👈

@ASH_hematology #ASH22 #MPNsm #HemOnc #AI

This year's #ASH22 meeting brought so many updates in multiple myeloma, including novel CAR-T therapies, BiTEs, trial updates, and more!

To stay up-to-date with the latest, visit our post-ASH virtual workshop on-demand content:

👉http://ow.ly/jhhB50MHyo6👈

#MMsm #ImmunoOnc

🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?

Check out our interview with @MosqueraOrgeira below:

👉http://ow.ly/zJYI50MzXgg👈

@ASH_hematology #ASH22 #MPNsm #HemOnc #AI

📣 Check out our latest weekly podcast, where you will hear from experts @mike_dickinson1 & Tycel Phillips (@LymphClinician), who share their highlights in NHL at #ASH22:

🎧: http://ow.ly/5whs50MHIP4

#LymSM #HemOnc #ImmunoOnc

Each time I read an #AMLsm paper report morphological leukemia free state (MLFS) as a response criterion I cringe! While MLFS is listed in ELN criteria, it is not validated as proxy for long term benefit & does not reflect meaningful short term benefit to patients! Do you agree?

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter